Graft versus host disease · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib monotherapy Variant #01 | — | R 81 964 | 28d | ~41.3 mo | ~30.3 mo | ~2 | ~R 163 929 PFS proxy · indirect | 17 |
Ruxolitinib monotherapy Variant #06 Partial | — | R 48 520 | — | — | — | ~1 | ~R 48 520 PFS proxy · indirect | 2 |
Belumosudil monotherapy Variant #01 | — | — | 28d | — | — | — | — | — |
Axatilimab monotherapy Variant #01 | — | — | 14d | — | — | — | — | — |
4 of 4 regimens shown